Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.196 Aug Supp INDENT-700-2019
- 10.197 Aug RRA-7.00-2019
- 10.198 Aug Supp INDENT-700-2020
- 10.199 Aug RRA-7.00-2020
- 10.200 Aug Supp INDENT-725-2022
- 10.201 Aug RRA-725-2022
- 10.202 Aug Supp INDENT-575-2022
- 10.203 Aug Supp INDENT-5375-2023
- 10.204 Aug RRA-5375-2023
- 10.205 Commitment Letter
- 21 09.30.2014 Subsidiaries
- 31.1 CEO 302 Certification
- 31.2 CFO 302 Certification
- 32.1 CEO 906 Certification
- 32.2 CFO 906 Certification
- Download Excel data file
- View Excel data file
Related press release
ENDPQ similar filings
Filing view
External links
Exhibit 10.199
EXECUTION VERSION
Counterpart to Registration Rights Agreement
August 11, 2014
The undersigned hereby absolutely, unconditionally and irrevocably agrees as a Guarantor, as defined in the Registration Rights Agreement, dated May 6, 2014 by and among Endo Finance LLC, a Delaware limited liability company and Endo Finco Inc., a Delaware corporation, the Guarantors party thereto, RBC Capital Markets, LLC and Deutsche Bank Securities Inc., relating to the 7.00% Senior Notes due 2020, to be bound by the terms and provisions of such Registration Rights Agreement.
Exhibit 10.199
IN WITNESS WHEREOF, the undersigned has executed this counterpart as of the date first written above.
DAVA PHARMACEUTICALS, INC. |
By: | /s/ Deanna Voss |
Name: | Deanna Voss |
Title: | Assistant Secretary |
[Signature to Registration Rights Agreement Counterpart - 7.00% Senior Notes due 2020]